United Kingdom
United Kingdom

The 'go to' European specialist pharma company

Our commercial partners

Ruslan Akhmadov,
Head of Alliance Management,
Takeda Russia-CIS

'Norgine is well structured to support alliances. It has alliance management function, it has project management function, and it has good continuity and support form marketing and regulatory teams.'

Pier Vincenzo Colli,
General Manager,
Alfa Wassermann

'Norgine is very strong, it has good marketing and market access capabilities. This is exactly what we were looking for. A company which can successfully place our products.'
  Partner Details
Acino In June 2016, Norgine divested its MENA operations and products to Acino.
Alizyme Alizyme In 2009, Norgine acquired all rights to CAMETOR® (cetilistat) for obesity from Alizyme.
Alfa Wassermann Alfa Wassermann

In 2008, Norgine acquired the commercialisation rights from Alfa Wassermann for rifaximin-α for gastrointestinal indications such as traveller’s diarrhoea and hepatic encephalopathy.

Norgine currently holds marketing rights for XIFAXAN® 550mg (known as TARGAXAN® 550 in the UK and some other markets) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, United Kingdom and Switzerland. Norgine and Alfa Wassermann co-promote the product under the TIXTAR® brand name in France.


Apharm s.r.l

In June 2015, Norgine entered an agreement with Apharm s.r.l. to distribute ZIVEREL® in Spain, Australia and New Zealand.

In 2016, Norgine extended its agreement with Apharm s.r.l to distribute ZIVEREL®  in addtional european countries. 

APR APR In 2011, Norgine in-licensed SETOFILM® (Ondansetron RapidFilm® 4mg and 8mg) for chemotherapy and radiotherapy induced nausea and post-operative nausea in adults and children from Applied Pharma Research s.a. (APR). Norgine's rights cover Europe, Australia, New Zealand, South Africa, North Africa and the Middle East.
Arc Medical Design Limited.                                    

In March 2015, Norgine partnered with Arc Medical Design Ltd. for endoscopic device, ENDOCUFF VISION®.

In April 2015, Norgine acquires a 70% stake in Arc Medical Design Ltd. while retaining Arc Medical Design existing management, who will retain a 30% ownership stake.

ASPEN logo Aspen

On 30 Sept. 2015, Norgine B.V. completed its agreement with Pharmacare Limited, a wholly owned subsidiary of Aspen Pharmacare Holdings (collectively “Aspen”) for the divestment of its Southern African operations and product rights.

China Medical System Holdings Limited             In December 2014, Norgine partnered with China Medical System Holdings Limited for MOVICOL® in China.
Clinigen Group plc SpePharm AG, an affiliate of Norgine B.V sells SAVENE® (dexrazoxane) to Clinigen Group plc. March 2014.
Difa Cooper Difa-Cooper Partner via the SpePharm joint venture.
Ajinomoto EA Pharma In 2008, Norgine out-licensed MOVIPREP® a bowel cleansing product, rights to EA Pharma for Japan.
Helsinn Helsinn In 1988, Norgine licensed-in KLEAN-PREP® - bowel cleansing product, from Helsinn.
Innovacell A.G. Innovacell A.G. In December 2013, Norgine and Innovacell entered into a collaboration and exclusive licensing agreement for Europe, SADAC and MENA regions for ICEF15/ NPJ5007, a phase II cell therapy product to treat faecal incontinence.
INRA INRA In 2009, Norgine in-licensed exclusive worldwide patent portfolio from L’Institut National Recherche Agronomique (INRA).
Jubilant Biosys Jubilant Biosys In 2011, Norgine entered into a research collaboration with Jubilant  Biosys. The collaboration is now terminated.
Meda Meda In 2012, Norgine divested over the counter products to Meda.
Medical Futures Medical Futures In 2008, Norgine out licensed MOVIPREP® - bowel cleansing product, rights to Medical Futures for Canada.
Merck Merck Sante France Partner via the SpePharm joint venture. DANTRIUM® IV and DANTRIUM® capsules. 
Modi-Mundipharma Modi-Mundipharma In 2010, Norgine out licensed MOVIPREP® - bowel cleansing product and MOVICOL® - constipation product, rights to Modi-Mundipharma for the Indian sub-continent.
 Molteni Molteni In 2003, Norgine in-licensed ORAMORPH® for moderate to severe pain.

Navidea Biopharmaceuticals Inc

In March 2015, Norgine and Navidea entered European partnership for LYMPHOSEEK®.
NÓOS srl  In September 2015, Norgine announced a new partnership with NÓOS srl to sell via a fostering agreement BioGaia® Gastrus™ in Italy. 
Image result for olympus corporation of americas Olympus Corporation of the Americas 

In May 2016, Norgine B.V. and its subsidiary Arc Medical Design Ltd entered into a new distribution agreement by which Arc appointed Olympus Corporation of the Americas as the exclusive distributor of ENDOCUFF VISION® in the US and Canada.


Pegasus Biosolution Pegasus Biosolution In 2012, Norgine entered into a pre clinical drug discovery with Pegasus.
Pfizer Germany

In 2016, Norgine enters co-promotion agreement with Pfizer in Germany for INFLECTRA® (infliximab) for the treatment of Crohn’s disease and ulcerative colitis.

PharmaSwiss / Valeant PharmaSwiss / Valeant In 2008, Norgine out licensed MOVIPREP® rights to Valeant for CEE territories.
PlasmaTech Biopharmaceuticals

In August 2014, Norgine entered into a license agreement with PlasmaTech Biopharmaceuticals Inc. to develop and commercialise the medical device, MUGARD® in Europe for the prevention and management of the lesions and symptoms of oral mucositis.  

In October 2014, Norgine B.V signs expanded licensing agreement with PlasmaTech Biopharmaceuticals for MUGARD® to now include Australia and New Zealand.
Salix Salix In 2005, Norgine out-licensed MOVIPREP® - bowel cleansing product, rights to Salix for the US.
Santarus Santarus In 2009, Norgine in-licensed ZEGERID®. The collaboration is now terminated.   
SpePharm SpePharm In December 2012, Norgine created a joint venture SpePharm AG. The joint venture acquired the products of SpePharm Holding B.V. (DANTRIUM® IV, DANTRIUM® capsules, SAVENE®, XEROTIN® and PROTHER®) for cash and equity. Separately Norgine acquired the commercial operations of SpePharm Holding B.V. in Italy, Germany, the UK and the Nordic region.
 Takeda Takeda In 2003, Takeda acquired the rights for development and commercialisation of CAMETOR® (cetilistat) known as OBLEAN® in Japan from Alizyme. The product is used to treat obesity. In 2009, all CAMETOR® rights were acquired by Norgine.

In 2011, Norgine out-licensed MOVIPREP® rights to Nycomed, now Takeda for Russia/CIS.
Tillotts Tillotts In 2000, Norgine in-licensed FIVASA® from Tillots for France.
Tranzyme Tranzyme In 2010, Norgine in-licensed TZP-101.  The collaboration is now terminated.
Valeant In 2016, Norgine licensed NER1006 (PLENVU) to Valeant Pharmaceuticals for US and Canada.